Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug quality and efficacy, with buyers shouldering the greater burden of risk in exchanges that are typically asymmetric. Drawing on in-depth interviews (N = 220) and observations of medicine transactions, plus interviews with regulators (N = 20), we explore how people in Ghana negotiate this uncertainty and come to trust a medicine enough to purchase or ingest it. We identify two mechanisms – attempts to mitigate uncertainty through seeking observable signs of quality and attempts to reduce informational asymmetry – that underpin cognitive assessments of a medicine's trustworthiness. However, these ‘cognitive’ forms of trust assessment have limited...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
In contexts where healthcare regulation is weak and levels of uncertainty high, how do patients deci...
The increased accessibility of medicines across the globe has expanded choice in therapeutic consump...
Trust is acknowledged to be centrally important to the operation of clinical trials. The processes o...
Providing access to quality-assured medicines is a fundamental component of strengthening health sys...
This article presents an ethnographic study of regulatory decision-making regarding the cost-effecti...
This article examines the “technological appraisals” carried out by the National Institute for Healt...
In 2012, the WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and f...
Abstract Background Building appropriate levels of trust in pharmaceuticals is a painstaking and cha...
Although trust is central to almost all human interactions, it is generally taken for granted and as...
Abstract Background Two billion people worldwide, pre...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
In contexts where healthcare regulation is weak and levels of uncertainty high, how do patients deci...
The increased accessibility of medicines across the globe has expanded choice in therapeutic consump...
Trust is acknowledged to be centrally important to the operation of clinical trials. The processes o...
Providing access to quality-assured medicines is a fundamental component of strengthening health sys...
This article presents an ethnographic study of regulatory decision-making regarding the cost-effecti...
This article examines the “technological appraisals” carried out by the National Institute for Healt...
In 2012, the WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and f...
Abstract Background Building appropriate levels of trust in pharmaceuticals is a painstaking and cha...
Although trust is central to almost all human interactions, it is generally taken for granted and as...
Abstract Background Two billion people worldwide, pre...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
Access to quality medicines is a universal human right which featured prominently on the agenda of t...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...